Spruce Biosciences, Inc (SPRB)

Etorro trading 970x250
Spruce Biosciences, Inc (SPRB) Logo

About Spruce Biosciences, Inc

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy, which is in Phase IIb clinical trial for adult patients with classic congenital adrenal hyperplasia (CAH) and in Phase II clinical trial in children with classic CAH. It is also developing tildacerfont for females with polycystic ovary syndrome. The company has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses. Spruce Biosciences, Inc. was founded in 2014 and is headquartered in Daly City, California. Address: 2001 Junipero Serra Boulevard, Daly City, CA, United States, 94014

Spruce Biosciences, Inc News and around…

Latest news about Spruce Biosciences, Inc (SPRB) common stock and company :

Benzinga's Top Ratings Upgrades, Downgrades For November 23, 2021
23 Nov, 2021 FinancialContent

Upgrades Keefe, Bruyette & Woods upgraded the previous rating for CBRE Group Inc (NYSE:CBRE) from Market Perform to ...

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference
18 Nov, 2021 FinancialContent

Spruce Biosciences to Participate in the Piper Sandler 33rd Annual Healthcare Conference

80 Biggest Movers From Yesterday
17 Nov, 2021 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares surged 55% to close at $1.00 on Tuesday as the company reported a ...

Benzinga's Top Ratings Upgrades, Downgrades For November 16, 2021
16 Nov, 2021 FinancialContent

Upgrades According to Maxim Group, the prior rating for VirTra Inc (NASDAQ:VTSI) was changed from Hold to Buy. For the ...

10 Biggest Price Target Changes For Tuesday
16 Nov, 2021 FinancialContent

B of A Securities cut the price target on Oatly Group AB (NASDAQ: OTLY) from $32 to $11. Oatly Group shares fell 0.6% to $9.30 in ...

Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates
15 Nov, 2021 FinancialContent

Spruce Biosciences Reports Third Quarter 2021 Financial Results and Provides Corporate Updates

Spruce Biosciences Appoints Mike Grey as Interim CEO
15 Nov, 2021 FinancialContent

Spruce Biosciences Appoints Mike Grey as Interim CEO

Spruce Biosciences Enters Oversold Territory (SPRB)
01 Nov, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Allogene Sinks On FDA Clinical Hold, Takeda Gets Adcom Backing, Quidel Reports Q3 COVID Revenues, IPOs
08 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results
07 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

RSI Alert: Spruce Biosciences (SPRB) Now Oversold
01 Oct, 2021 FinancialContent

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100..

The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
01 Oct, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: AbbVie's Migraine Drug OK'd By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
29 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Click here for accessing Benzinga's FDA ...

The Daily Biotech Pulse: Restricted Authorization For Pfizer's COVID-19 Booster Dose, AbCellera Strikes Antibody Licensing Deal, Solid Biosciences Issues DMD Data
23 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Pfizer-BioNTech US Vaccine Contract, Summit Slumps On Adverse Regulatory Feedback, Cerevel CFO Departs
22 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data
21 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Leap, Phio, Silverback Among Early Movers On Oncology Conference Presentations, Aerie Slumps On Mixed Data, Axsome Commences Phase 3 Sleep Disorder Study
16 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs
15 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Spruce Biosciences to Participate in September Investor Conferences
07 Sep, 2021 FinancialContent

Spruce Biosciences to Participate in September Investor Conferences

Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day
25 Aug, 2021 FinancialContent

Spruce Biosciences Announces Pediatric Classic CAH Program Details During Virtual R&D Day

The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
17 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
13 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Lows On Thursday
12 Aug, 2021 FinancialContent

During Thursday's morning trading, 83 companies set new 52-week lows. Intriguing Points: KE Holdings ...

The Daily Biotech Pulse: Xeris Gets OK For Initiating Hyperthyroidism Study, Merck-Eisai Snag FDA Approval For Drug Combo, Decision Day For Jazz Pharma
12 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Spruce Biosciences to Host Virtual R&D Day on August 25, 2021
11 Aug, 2021 FinancialContent

Spruce Biosciences to Host Virtual R&D Day on August 25, 2021

Spruce Biosciences Expands Tildacerfont Portfolio with Potential Treatment for Polycystic Ovary Syndrome
11 Aug, 2021 Yahoo! Finance

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Late-stage biopharmaceutical company Spruce Biosciences Inc (NASDAQ: SRPB) reported financial results for the second quarter ended June 30, 2021 and announced that it has submitted an investigational new drug application (IND) for tildacerfont in the treatment of polycystic ovary syndrome (PCOS), which has recently been cleared by the FDA. Til

The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering
11 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Spruce Biosciences Reports Second Quarter 2021 Financial Results and Provides Corporate Updates
10 Aug, 2021 FinancialContent

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update.

Why Earnings Season Could Be Great for Spruce Biosciences (SPRB)
10 Aug, 2021 Yahoo! Finance

Spruce Biosciences is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Spruce Biosciences, Inc (SPRB) is a NASDAQ Common Stock listed in , ,

970x250